Clover Health Investments, Corp. - Class A Common stock (CLOV)
3.5500
+0.1400 (4.11%)
NASDAQ · Last Trade: May 18th, 5:57 PM EDT
Detailed Quote
Previous Close
3.410
Open
3.410
Bid
3.450
Ask
3.460
Day's Range
3.405 - 3.580
52 Week Range
0.8638 - 4.870
Volume
5,306,188
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
5,793,949
Chart
About Clover Health Investments, Corp. - Class A Common stock (CLOV)
Clover Health Investments Corp is a healthcare technology company focused on improving the health outcomes of Medicare beneficiaries. By utilizing its proprietary data-driven platform, Clover Health aims to enhance care delivery and streamline operations for its members, promoting preventive care and tailored health services. The company partners with healthcare providers to deliver more efficient and personalized care, ultimately seeking to reduce costs and improve patient satisfaction in the healthcare system. Through innovation and technology, Clover Health strives to make healthcare more accessible and effective for seniors across the United States. Read More
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%.
But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
Clover Health Investments saw its shares jump more than 12% on Wednesday. Following better-than-expected profitability in the first-quarter, despite missing revenue estimates.
Shares of health insurance company Clover Health (NASDAQ:CLOV) jumped 13.6% in the afternoon session after the company reported strong first quarter 2025 results which significantly beat analysts' EPS expectations and included full-year EBITDA guidance above Wall Street estimates. On the other hand, while membership in their Medicare Advantage plans jumped 30%, pushing revenue up 33%, sales still came in just under what analysts expected. Overall, we think this was a decent quarter with some key metrics above expectations.
Health insurance company Clover Health (NASDAQ:CLOV) fell short of the market’s revenue expectations in Q1 CY2025, but sales rose 33.3% year on year to $462.3 million. Its GAAP loss of $0 per share was significantly above analysts’ consensus estimates.
A cash-heavy balance sheet is often a sign of strength, but not always.
Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 10.9%. This performance was worse than the S&P 500’s 5.6% decline.
Even during a down period for the markets, Clover Health has gone against the grain, climbing to $3.82. Its shares have yielded a 26.1% return over the last six months, beating the S&P 500 by 27.7%. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
Let’s dig into the relative performance of Clover Health (NASDAQ:CLOV) and its peers as we unravel the now-completed Q4 health insurance providers earnings season.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the health insurance providers industry, including Centene (NYSE:CNC) and its peers.
Let’s dig into the relative performance of Cigna (NYSE:CI) and its peers as we unravel the now-completed Q4 health insurance providers earnings season.
Stocks recovered on Friday, with all three major indexes in the green, as the tech sector bounced back from Thursday's losses with NVIDIA Corp. (NASDAQ:NVDA) up 1.37% and Tesla, Inc. (NASDAQ:TSLA)
Health insurance company Clover Health (NASDAQ:CLOV) missed Wall Street’s revenue expectations in Q4 CY2024, with sales falling 34% year on year to $337 million. Its GAAP loss of $0.04 per share was $0.03 above analysts’ consensus estimates.
The S&P 500 and Nasdaq both slipped into the red, reversing early gains on Thursday, while the Dow Jones remained in positive territory in midday trading.
